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Abstract 
 
Background: Multiple Sclerosis (MS) is an immune-mediated disease of the 
central nervous system which responds to therapies targeting circulating 
immune cells.  
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Objective: To test if the T cell activation gene expression pattern (TCAGE) we 
had previously described from whole blood was replicated in an independent 
cohort.  
Methods: We used RNA-seq to interrogate the whole blood transcriptomes of 72 
individuals (40 healthy control, 32 untreated MS). A cohort of 862 control 
individuals from the Brisbane Systems Genetics Study (BSGS) was used to assess 
heritability and seasonal expression. The effect of interferon beta (IFNB) therapy 
on expression was evaluated. 
Results: The MS/TCAGE association was replicated and rationalised to a single 
marker, ribosomal protein S6 (RPS6). Expression of RPS6 was higher in MS than 
controls (p<0.0004), and lower in winter than summer (p<4.6E-06). The 
seasonal pattern correlated with monthly UV light index (R=0.82, p<0.002), and 
was also identified in the BSGS cohort (p<0.0016). Variation in expression of 
RPS6 was not strongly heritable. RPS6 expression was reduced by IFNB therapy.  
Conclusions: These data support investigation of RPS6 as a potential 
therapeutic target and candidate biomarker for measuring clinical response to 
IFNB and other MS therapies, and of MS disease heterogeneity.   
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Introduction 
MS is an autoimmune disease of the central nervous system caused, at least in 
part, by pathogenic leukocytes which transit from lymphoid tissue to the brain 
via the peripheral circulation.1 This paradigm is supported by the success of 
immunomodulatory therapies such as Natalizumab, which prevents activated T 
cell migration across the blood-brain barrier from the peripheral circulation2; 
and of Fingolimod, which blocks egress of activated T cells from the lymph 
nodes.3  It is also supported by studies on genetic susceptibility4, since the 
majority of identified genes associated with MS are predominantly expressed in 
immune cells, especially the dendritic cell/ T cell axis.4  Monitoring changes in 
the numbers and states of these cells may identify pathogenic processes, useful 
biomarkers of susceptibility, molecular subtypes of diseases, response to 
therapy, and new therapeutic targets.  
 
Earlier, we had reported mRNA expression for all known genes in whole blood 
from 144 individuals, 99 of whom had untreated MS.5  We had used PAXgene 
blood collections, which capture transcriptomes immediately on blood draw, 
rather than peripheral blood mononuclear cell (PBMCs) methods, which are less 
reproducible.6 Analysis of gene expression and genotype indicated the dominant 
pattern of dysregulation of T cell gene expression in MS in these individuals is 
matched with the genetic associations from the GWAS4 pointing to T cell 
dysregulation in MS.  We identified a T cell activation gene expression (TCAGE) 
signature in whole blood that predicted the likelihood of MS.  This signature 
reflects excess expression of genes upregulated on T cell activation and 
proliferation, mainly from translation and oxidative phosphorylation metabolic 
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pathways.5 This TCAGE signature needed to be confirmed in an independent 
cohort, and potentially simplified. The effect of therapy on the TCAGE is 
currently unknown, and the heritability of this signature is also not established. 
 
In this study, we have first tested if next generation sequencing of messenger 
RNA (RNA-seq) could be used to interrogate gene expression in whole blood 
samples by comparing expression measured by both techniques (RNA-seq and 
microarrays) for the same samples. We then used RNA-seq to assay whole blood 
transcriptomes for 40 healthy controls and 32 people with untreated MS. The 
TCAGE signature could be rationalized to a single gene, ribosomal protein S6 
(RPS6). We have tested if RPS6 expression is affected by genotype. Finally, 
interferon beta (IFNB
thought to function by immunomodulation.7 We have tested if RPS6 expression 
is altered by therapy. 
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Materials and Methods 
Sample Collection 
RNA-seq Cohort: For the RNA-seq experiment, a single PAXgene blood RNA tube 
(PreAnalytiX, Switzerland) was collected from people with MS who were not 
receiving any treatment, and had not received any immunomodulatory therapy 
in the previous three months, from clinics in Sydney and Adelaide. Blood was 
also collected from healthy controls of matching ages and not receiving 
immunomodulatory therapy. Demographics for patients and controls are 
described in Table 1.  
Brisbane Systems Genetics Study (BSGS) cohort: This cohort comprises 862 
individuals of European descent from 312 independent families8 located within 
the greater Brisbane region. For each cohort informed written consent was 
obtained from each donor, and the study was approved by the Human Research 
Ethics Committee (HREC) from Sydney, Adelaide and Brisbane. 
IFNB therapy cohort: 
of anonymised donors who were identified as MxA bioactivity positive or 
negative by bioactivity testing.9 Approval to use these samples was also granted 
by SWAHS HRECS.  
 
RNA-seq  
Whole blood: Total RNA was isolated from PAXgene RNA blood tubes using the 
PAXgene Blood RNA Kit (Qiagen, Germany), and subsequently treated with 
Globinclear (Life Technologies, NY, USA), to deplete the whole blood sample of 
alpha and beta globin mRNA. RNA was then prepared for sequencing on Illumina 
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HiSeq 2000 using the Illumina TruSeq RNA sample preparation kit V1 (Illumina, 
CA, USA).  Samples were indexed and 6 run per lane, generating at least 10 
million 50bp reads per sample. Raw sequence data was aligned to the UCSC 
human reference genome (hg19) using the Tophat software package.10 Aligned 
sequencing reads were summarised to counts per gene using the Read 
Assignment via Expectation Maximiation (RAEM) procedure11 and reads per 
kilobase per million mapped reads (RPKM)  values calculated in SAMMate (v 
2.6.1). RPKM values were transformed by quantile normalisation prior to 
visualization using BRB-Array Tools.12 Visualisation was performed by 
performing hierarchical clustering using 1 minus correlation and average linkage 
metrics. The microarray gene expression analysis has been previously described 
in5 for the ANZgene cohort, and in13 for the Brisbane Systems Genetic Study.  
 
Quantitative RTPCR 
Primers were designed to amplify across the last two exons of RPS6 -
RPS6F:GCGGCGTATTGCTCTGAAGA, RPS6R: GCAGAGAGGAAAGTCTGCGT. cDNA 
was made using SuperScript™ III Reverse Transcriptase (Invitrogen, San Diego, 
CAL), and RTPCR was performed using Power SYBER Green PCR Master Mix 
(Applied Biosystems, Carlsbad, CAL) at an initial 30sec 95°C denaturation, 30sec 
64°C annealing and 30sec 72°C extension for 5 cycles, then 30sec 95°C 
denaturation, 30sec 60°C annealing and 30sec 72°C extension for 40 cycles, 
followed by a melt curve of 15sec 95°C, 15sec 55°C and 15sec 95°C. 
Quantification was by comparison to GAPDHF:ACGCATTTGGTCGTATTGGG, 
GAPDHR: TGATTTTGGAGGGATCTCGC , as previously described.14 
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Statistical Analysis 
Firstly, both the pooled ANZgene cohort and individual RNA-seq data were 
analysed using the statistical package, EdgeR.15 EdgeR was used to assess 
differences in gene expression between MS and controls. Genes expressed at >25 
reads per million total reads and calculated to be differentially expressed with 
FDR<10% were identified (Supplementary Table 1). Secondly, using the data 
obtained by RNA-seq, all genes with a minimum RPKM value greater than 100 
were selected for further analysis (344 genes). To account for differences in 
expression levels, for each gene the expression level was ranked across 
individuals, and ranked data used to test correlations between genes.  Further 
details are provided in figure legends and the supplementary information 
section.  
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Results 
Replication of the TCAGE in an independent cohort using RNA-seq 
We interrogated whole blood gene expression using mRNA from blood collected 
into PAXgene tubes, and RNA-seq to assess gene expression. To test the RNA-seq 
protocol, we first prepared two cDNA libraries from pooled mRNA from 20 MS 
patients and 20 healthy controls (HC) used in the ANZgene microarray 
experiment reported earlier,5 and measured expression of the transcriptome 
using Hiseq2000 to 30 million reads per pool. All 38 TCAGE genes expressed at 
>25 reads per million reads were more highly expressed in MS, 16 of these at 
p<0.001 (Fig. 1, Supplementary Table 1A, Fig. S1). Half of these 16 were genes 
encoding ribosomal proteins. We then prepared RNA-seq libraries from an 
independent collection of whole blood from 40 HC and 32 untreated MS patients 
(cohort traits detailed in Table 1), and measured transcriptomes to a depth of 
>10 million reads per sample. We used EdgeR to assess the relative expression of 
all genes expressed with at least 25 reads per million reads in all samples. Of the 
26 TCAGE genes in this list 12 were ribosomal protein genes, all of which were 
more highly expressed in MS (12/12, p<0.0005).  This low p value is indicative 
only, since these genes are likely to be coordinately regulated.  Since our second 
study was smaller than the first, we used a permissive FDR of 10% to define a 
dysregulated gene set (genes listed in Supplementary Table 1B). Ribosomal 
protein genes are again over-represented.  
 
We then tested the cellular pathways that were over-represented, and the 
immune cell subsets tagged, by these genes; and compared these with those 
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identified in our previously published microarray study. Again, over-expressed 
genes were predominantly expressed in T cells (Fig. 2a), underexpressed genes 
predominantly expressed in other immune cell subsets (Fig.  2b), and the most 
dysregulated pathways were those involving the ribosomal protein genes (Fig. 
2c). 
 
RPS6 is a surrogate marker for ribosomal protein and other TCAGE 
genes 
If the ribosomal protein (RP) genes are coordinately expressed, measurement of 
one should provide a proxy for regulation of all.  From these data, we chose RPS6 
as the most highly associated with MS (p<0.00036, t test on RPKM ranks), and 
compared the rank of its expression with the sum of the ranks of all TCAGE genes 
in each individual. Expression of RPS6 was tightly correlated with the expression 
of all 12 RP genes (R= 0.93, p< 1.96E-25, Fig. 3a), with all 26 TCAGE genes 
(R=0.85, p<1.65E-18), and with the 14 nonRP genes in the TCAGE list (R=0.70, 
p<1.87E-11). By comparing the aligned reads from the RNA-seq analysis of 
pooled MS and HC samples, it can be seen that exon usage for RPS6 was the same 
in MS and HC (Fig. 3b inset). We designed primers from across the exon 4-5 
boundary and compared RPS6 expression by RTPCR with the RPKM 
measurement from RNA-seq. Measurements from both techniques were highly 
correlated (R=0.93, p=2.73E-24, Fig. 3b). 
 
RPS6 expression is seasonal 
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In the RNA-seq cohort age and gender were not associated with RPS6 expression 
(Fig S6), but season was (Fig. 4b). We analysed the data using month of sample 
collection, with months classified as Summer or Winter on the basis of RPS6 
expression: In Summer - October-March – RPS6 expression was highest ; Winter 
- April-September, lowest expression.  
 
Overall, in the RNA-seq cohort RPS6 expression was higher in MS than HC (Fig. 
4a, p<0.003). However, this difference was only evident in winter (p<0.00019) 
with a trend in summer (Fig. 4b, p=0.19).  The seasonal difference for HC (Fig. 4, 
p<7.2E-8) and MS patients (p<0.004) was also highly significant. Similar 
differences were seen in the ANZgene microarray cohort (Fig. 4a), with a 
significant difference between MS and controls in summer (p<0.0002). The RPS6 
seasonal pattern was confirmed in a third large cohort of HC from the sub-
tropical city of Brisbane (p<0.0016, Fig. S2). In both the RNA-seq cohort (R=0.82, 
p< 0.002) Fig. 5b) and the Brisbane cohort (p<0.01, Fig. S2) the RPS6 expression 
correlated with UV radiation. Although RPS6 expression in the RNA-seq cohort 
did not correlate with Vitamin D levels (R=0.27, ns, Fig5), correlation increases if  
two months out of phase, with RPS6 increasing two months earlier than Vitamin 
D (R=0.71, p<0.011).   No diurnal effect on RPS6 expression was detected in 5 
individuals assayed at 4 time points (Supplementary Methods, Figure S3).  
Using Receiver Operator Curves, where the expression of RPS6 was 95% 
sensitive to detect MS, the specificity was 43%, with an area under the curve of 
0.72, p=0.0012 (Fig. 6). In winter, this specificity improves to  67%,   and the area 
under the curve to 0.92, p<0.0001. In summer RPS6 expression was not 
predictive of MS.  
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Because some studies but not others16 have indicated month of birth affects on 
MS risk, and RPS6 regulation might be set by imprinting, we tested if expression 
was associated with month of birth. There was no association. 
 
Relative expression of ribosomal protein genes in immune cell subsets 
To identify the cell subsets contributing to the difference in the RP signature 
between MS and HC, we interrogated transcriptomes from 23 immune cell 
subsets in whole blood using RNA-seq (Fig. 7, Supplementary Methods), and 
compared this to in silico data for the subsets.17, 18 The expression level between 
subsets was consistent (Figure S4). RPS6 and other ribosomal protein genes 
were most highly expressed in CD4 and CD8 T cells. 
 
RPS6 expression is altered by interferon beta 
We measured RPS6 expression 9-15 hours after IFNB injection in 32 MS patients, 
16 of which were classified as responders to IFNB, as indicated by MxA 
upregulation, whilst 16 were classified as non-responders. The difference 
between the two is considered to be due to the development of neutralizing 
antibodies in the latter.9 RPS6 expression was lower in the IFNB responsive 
group when compared to the non-responsive MS patients in both summer 
(p=0.018) and winter (p=0.006).  In addition, the RPS6 expression was lower in 
MS patients, classified as IFNB responders when compared to controls in 
summer (p=0.046) and winter (p=0.079). The non-responders exhibited higher 
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RPS6 expression than controls in summer (p=0.003) and winter (p=0.006), and 
they had similar expression of RPS6 to untreated MS (Fig. 8). 
 
RPS6 expression is not strongly heritable 
Expression profiles were collected for the 862 individuals from extended MZ and 
DZ twin families in Brisbane System Genetics Cohort (BSGS) using Illumina HT12 
v.40 arrays.13 Genotypes for each of these individuals were also determined 
(Illumina 610-Quad Beadchip). Family relationships among individuals within 
BSGS were used to estimate the additive genetic component of expression 
variation for the two probes in RPS6 using ASREML.19 Heritabilities (h2) for the 
two probes were estimated by the ratio of additive genetic variation to total 
phenotypic variation. Estimates of h2 for the two RPS6 probes on this chip were 
zero, even after correcting for month of sample collection, suggesting that any 
variation in the expression levels of the two probes is due to environmental 
factors, at least for whole blood. None of the 528,509 SNPs on this chip were 
significantly correlated with RPS6 expression. 
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Discussion 
Using an independent cohort and alternative method of transcriptome 
interrogation, we have replicated our original finding that a set genes 
predominantly expressed in T cells, notably the ribosomal protein (RP) genes, 
are overexpressed in MS. Measurement of expression of one gene, RPS6, could be 
used as a surrogate for the expression of the other RP and TCAGE genes. As well 
as disease state, RP gene expression was highly affected by season. Higher 
expression was seen in the late spring, summer months than winter and early 
spring, mirroring the UV light seasonal pattern. We found no evidence that the 
expression pattern was heritable, suggesting that the difference in expression 
between MS and HC was caused by disease and/or environmental factors. RPS6 
whole blood expression was also reduced on IFNB therapy. 
 
Ribosomes are made up of equimolar amounts of each of the 80 ribosomal 
proteins, so that co-ordinate regulation of RPs is to be expected,20 and is 
observed in this study. However, there are extra-ribosomal functions, and 
variable phosphorylation of the ribosome constituent proteins, so that cell 
subsets have subtle but important differences in their RP transcriptomes.21 RPS6 
is essential for ribosome biogenesis, is phosphorylated at evolutionarily 
conserved residues, and regulates protein synthesis, cell growth and 
proliferation, but also has specific features which have led to its intensive 
investigation as a biomarker.22 It is most highly expressed in lymphocytes, 
especially naïve T cells (Fig 817, 18). It controls metabolic signaling in CD8 T 
cells;23 has been reported to be a predictor of resistance to therapeutic inhibition 
of FLT3 targeting leukemic blasts;24 and predicts sensitivity to the inhibitor of 
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immune cell proliferation, mTOR.25 Higher expression of RPS6 in PBMCs was 
observed in people with MS more likely to relapse.26 A gene regulating RPS6 
phosphorylation, RPS6KB1, is associated with MS susceptibility. Phosphorylation 
of RPS6 is downstream of mTOR activation, and therapeutic inhibition of mTOR 
by drugs such as rapamycin increase the proportion of Tregs to Th1 and Th17 
cells.27 These data support a role for RPS6 in MS susceptibility, pathogenesis, 
therapeutic response, and as a target for novel therapies.  
 
Immune cell expression of RPS6 is higher throughout the year in untreated MS 
patients, suggesting a greater T cell proliferation/activation, which may be 
enough to increase risk of development of MS and relapses.  MS onset and 
relapses are most common in spring/summer in both the northern and southern 
hemispheres.28, 29  This is when UV light and RPS6 expression start to increase 
and before serum vitamin D increases. Seasonally corrected serum vitamin D 
levels correlate with reduced risk of onset and relapses in MS, in both 
hemispheres 29.  
 
Demands on the immune system are clearly seasonal, and immune cell subsets 
numbers and proportions in whole blood fluctuate.30, 31 Although the regulators 
of the seasonal pattern are not known, they could include melatonin, light 
sensitive hormones such as vitamin D, and UV light factors independent of 
vitamin D.32 The seasonal fluctuation in serum 25D levels is some two months 
out of phase with the RPS6 and UV light fluctuation. This could indicate RPS6 
expression is immediately responsive to UV light, or that immediate vitamin D 
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fluctuation due to UV light affects immune cells more than serum vitamin D 
levels. 
 
IFNB has been the most commonly prescribed drug for MS, with many possible 
mechanisms of action proposed.33  These include regulation of the balance of 
immune cell subsets. We have shown that the RPS6 signal is greatly reduced on 
IFNB therapy.  This may be affected by a number of factors: reduced T cell 
activation and proliferation as a therapeutic response, reduced RPS6 
transcription on therapy, or to altered T cell representation in whole blood after 
injection due to trafficking of immune cell subsets. Reduced lymphocyte and 
neutrophil numbers, but greatly increased monocyte numbers were seen in 
whole blood after injection, 34 and altered immune cell state might also be 
expected. RPS6 whole blood levels would be expected to drop, as observed in the 
current cohort. Whether this reduction is correlated, or even underpins clinical 
response needs to be determined.  
 
A major limitation of using whole blood is that particular immune cell subset 
differences are difficult to identify.  In this case, although RPS6 expression is 
predominantly from T cells (Fig. 6), the cell subset source of the RPS6 difference 
between MS and controls will now need to be established using flow cytometry. 
Cell subsets which vary by season, and in interferon response,  have previously 
been described,31,32,34 but which of these, or of other subsets, contribute to the 
RPS6 seasonal fluctuation and IFNB response will also need to be established 
through flow cytometric methods.  Another limitation of this study is that the 
RNAseq cohort controls and some MS patients were from Sydney, and many MS 
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patients but no controls were from Adelaide. No confounding factors between 
the two regions are known eg they have similar UV light levels (Fig 4), but its 
possible.  
 
High RPS6 expression, fold change between seasons, or discrepancy between 
RPS6 and other physiological parameters such as serum vitamin D, may indicate 
MS susceptibility and state, but also a molecular subtype of MS particularly likely 
to respond to certain therapies. Testing such possibilities is vital to developing 
cost-effective therapies in autoimmune diseases.35 
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Figure Legends 
 
Figure 1. Heat map of TCAGE gene expression in RNA-seq and ANZgene 
cohorts.  
Rows are expression of the most highly expressed T cell activation genes (TCAGE) 
identified in Gandhi et al (2010)
6
 plotted against the healthy controls and MS patients, 
sorted by season, for the ANZgene cohort (from pooled RNA-seq) and the RNA-seq 
cohort. For the latter, each individual is a column. Columns sorted by month of 
collection. Orange is high expression, blue is low.   
 
Figure 2. Heat map of Immune Cell Subset Expression of Genes Dyregulated in 
MS in the RNA-seq Cohort. Rows are the genes identified as dysregulated in the 
RNA-seq cohort (expression > 25 reads per million read, FDR 10%), columns the 
immune cell subsets (detailed in the Methods section). A. Genes overexpressed in 
MS, B. Genes underexpressed in MS, C. Pathways overrepresented in the over-
expressed genes. This is determined for the 552 genes with the lowest p values 
(corresponding to the number identified as differentially expressed at 10% FDR in the 
microarray analysis by
5
) in both cohorts, and the 10% FDR list from the RNA-seq 
cohort. These lists were uploaded into Metacore (GeneGo, USA) and tested for over-
representation in curated biological pathways (Figure 2C). 
 
Figure 3. RPS6 expression is correlated with expression of other ribosomal 
genes.  
A. Rank of RPS6 expression in 72 individuals, measured by RNA-seq, and Sum of 
Ranks of expression of all other Ribosomal Genes for those individuals. 
Correlation=0.93 B. Primers designed from exon usage in MS and Controls (inset) 
and  the linear correlation of RTPCR and RNA-seq measurement of RPS6 is 0.95. 
 
Figure 4. RPS6 expression in whole blood is dependent on season and disease 
state.  
A. Comparison of RPS6 expression in the RNA-seq cohort (this study) and the 
ANZgene cohort, published in Gandhi et al, 2010.
6
 RPS6 is measured by reads per 
kilobase per million mapped reads (RPKM) for RNA-seq, and by fluorescence on 
microarrays (ANZgene). Data are from normalised expression, compared using two-
tailed T tests. B. Effect of season on RPS6 expression in the RNA-seq cohort. 
  
Figure 5. RPS6 expression is affected by season and is correlated with UV 
radiation and Vitamin D levels.  
A. Top graph is RPS6 expression in each month, middle graph is UV index for 
different localities used as the source of samples (Australian Bureau of Meteorology 
website: http://www.bom.gov.au/), lowest graph is Vitamin D levels in NSW.
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 B. 
Correlation of RPS6 expression with UV radiation (R=0.83), Vitamin D (R=0.25), 
and Vitamin D, two months out of phase (R=0.70). R is the correlation co-efficient, 
determined from a linear correlation. 
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Figure 6. Receiver operator curves to predict MS from RPS6 expression 
Figure 7. RPS6 is predominantly expressed in T cells.  
Heat map shown for immune cell subsets (columns) and most expressed ribosomal 
protein genes, including RPS6 (rows). Colour is proportional to expression, with 
orange high expression and blue low expression. Immune cell subsets are defined in 
Supplementary Material and Methods. 
 
Figure 8.  Effect of Interferon Treatment on RPS6 Expression.  
People with MS on interferon beta without neutralizing antibodies (IFN (R)), had 
lower RPS6 expression than healthy controls (HC), those treated with interferon but 
with neutralizing antibodies (IFN (NR)), and people with MS (MS). The latter did not 
differ from IFN (NR). Each comparison for the IFNB treatment was assessed using 
the two tailed T test, with no correction for multiple testing. 
 
 
 
 
 
 
